Hosted by The Lancet HIV · EN-UK · 90 episodes
Established thought leaders with verified media credentials.
The Lancet HIV launched in autumn 2014, joining the growing collection of Lancet specialty journals. As an exclusively online journal, this new monthly title delivers a holistic view of the pandemic, publishing original research, comment, and correspondence that unifies clinical, epidemiological, and operational disciplines across a single vision of health for those living with HIV.
The Lancet HIV hosts Listen to The Lancet HIV, a science show with 90 episodes published.
Adrian Gonzalez entrevista a Claudia Cortes (Universidad de Chile, Santiago de Chile) y Giovanni Ravasi (Equipo de América Latina y Caribe del Fondo Mundial, Ginebra, Suiza) sobre los desafios a los que se enfrentan las
Adrian Gonzalez is joined by Jose M. Zuniga (IAPAC, Fast-Track Cities Institute and UNAIDS Task Force on Urban Health) to talk about the IAPAC – Lancet HIV Commission on the future of urban HIV responses.
Dr Amy Justice (Yale University, USA) talks to Philippa Harris about the joint The Lancet HIV and The Lancet Healthy Longevity Series Ageing with HIV.
Peter Hayward talks to Dr Bridget Mugisa (WHO, Eastern Mediterranean Office, Egypt) about a study summarising the epidemiology of HIV in the Middle East and north Africa.
Florence Riako Anam (Global Network of People Living with HIV, Kisumu, Kenya) and Bruce Richman (Prevention Access Campaign in New York, USA) join Adrian Gonzalez to discuss the importance of a clear message on U=U to en
Sharon Lewin (Peter Doherty Institute for Infection and Immunity, Melbourne, Australia) joins Deputy Editor, Adrian Gonzalez to talk about the requirements and challenges to develop a product for HIV cure based on cell a
People living with HIV often have many health needs beyond their antiretroviral medication. Editor in Chief Peter Hayward talks to Colette Smith about results of the Positive Voices survey identifying unmet health needs
Ageing with HIV brings new challenges. Even with effective ART, people ageing with HIV face increased risk of parkinsonism. Eran F Shorer from the Icahn School of Medicine at Mount Sinai joins us to explore the latest re
Controlling the HIV epidemic depends on shifting from fragmented, donor-led programmes to nationally led, integrated health systems. To accompany a new joint Series of six papers, Peter Hayward, Editor-in-chief of The La
Why do some people living with HIV struggle with sleep? Luxena Sukuraman and Alan Winston help us understand the challenges of disordered sleep in HIV, what clinicians can do to help, and practical sleep hygiene tips for
In the ongoing search for an HIV cure, promising evidence suggests that early treatment of infants might help achieve lasting HIV remission: the IMPAACT P1115 study is designed to investigate that potential. We talk to a
Jayne Ellis from the London School of Hygiene and Tropical Medicine discusses new research showing why targeting cytomegalovirus could be key to improving outcomes for people living with advanced HIV.
Maggie Walters and Michelle Bulterys talk us through their research into factors that affect the probability of vertical transmission and what it says about efforts to end new infant acquisitions.
Mansoor Farahani, Wafaa El-Sadr, and Wilford L. Kirungi discuss the strategies behind Uganda’s success, the challenges that still lie ahead, and how a current global funding crisis could impact the fight against HIV in t
In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results.
Join Adrian Gonzalez in conversation with Grace Lui and Vincent Wong (The Chinese University of Hong Kong) as they discuss whether a dietary and exercise programme can reduce liver fat and induce resolution of MASLD in p
Peter Hayward is joined by Debra ten Brink and Rowan Martin-Hughes of the Burnet Institute (Melbourne, Australia) as they discuss their modelling study forecasting the effects of funding cuts on HIV acquisitions and mort
Sari Reisner (University of Michigan School of Public Health, Boston, USA) on gender-affirming hormone therapy for transgender, non-binary, and gender-diverse people in the US and its effects on HIV acquisition risk and
Lisa Noghuchi of Jhpeigo (Johns Hopkins University) and Nyaradzo Mgodi (University of Zimbabwe) join Peter Hayward to discuss the MTN-043 study assessing safety and drug exposure of the dapivirine ring in breastfeeding w
Editor-in-Chief Peter Hayward is joined by Adrian Gonzalez (Deputy Editor) and Richard Henderson (Senior Editor) to reflect on 10 years since the launch of The Lancet HIV.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Listen to The Lancet HIV has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Listen to The Lancet HIV is hosted by The Lancet HIV. The show is categorised under science (medicine) and has published 90 episodes.
Listen to The Lancet HIV has published 90 episodes.
Listen to The Lancet HIV regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Listen to The Lancet HIV is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to The Lancet HIV hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to The Lancet HIV average 22 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to The Lancet HIV's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 11 days ago.
